Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.46 |
| ▸ | EED | O75530 | 3/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010573 | 0.87 | MTNR1A (0.55) | TAAR1MTNR1AHTR2A | |
| SCHEMBL29467994 | 0.84 | EED (0.46) | EEDABCG2KDM4CMTNR1AHTR2A | |
| SCHEMBL700738 | 0.84 | EED (0.46) | EEDABCG2KDM4CMTNR1AHTR2A | |
| SCHEMBL30360690 | 0.81 | KDM4C (0.46) | EEDABCG2KDM4CMTNR1AHTR2A | |
| SCHEMBL11044001 | 0.81 | EED (0.44) | EEDABCG2KDM4CMTNR1AHTR2A | |
| SCHEMBL8096405 | 0.81 | EED (0.44) | EEDABCG2KDM4CMTNR1AHTR2A | |
| SCHEMBL4130192 | 0.81 | KDM4C (0.46) | EEDABCG2KDM4CMTNR1AHTR2A | |
| SCHEMBL7771835 | 0.81 | KDM4C (0.46) | EEDABCG2KDM4CMTNR1AHTR2A | |
| SCHEMBL19772837 | 0.81 | MTNR1A (0.45) | EEDABCG2KDM4CMTNR1AHTR2A | |
| SCHEMBL23891754 | 0.78 | MTNR1A (0.48) | EEDABCG2KDM4CMTNR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010136037-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2010-12-02 | — | — | WO | claimed |
| CN-107163047-B | Sophoridine amine derivative and preparation method and application thereof | 中国医学科学院医药生物技术研究所 | 2021-04-23 | — | — | CN | disclosed |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | ACTION MEDICAL TECHNOLOGIES, LLC | 2018-11-08 | — | — | US | disclosed |
| US-10053468-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
| EP-3018126-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-05-11 | — | — | EP | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| US-7985753-B2 | Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-07-26 | — | — | US | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
| US-20070299130-A1 | Benzopyran Compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-12-27 | — | — | US | disclosed |
| WO-1995007260-A1 | TETRAHYDROISOQUINOLINES AS ALPHA-2 ANTAGONISTS AND BIOGENIC AMINE UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-03-16 | — | — | WO | disclosed |
| US-5389638-A | Nervous system disorders | ABBOTT LABORATORIES (US) | 1995-02-14 | — | — | US | disclosed |
| US-5231181-A | PROCESS FOR THE PREPARATION OF (8AS,12AS,13AS)-DECAHYDROISOQUINO ((2,1-G) (1,6)-NAPHTHYRIDIN-8-ONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1993-07-27 | — | — | US | disclosed |
| EP-0505183-A2 | Process for the preparation of (8aS,12aS,13aS)-decahydroisoquino[2,1-g][1,6]-naphthyridin-8-one derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-09-23 | — | — | EP | disclosed |
| US-5112851-A | Agricultural Fungicides | SANDOZ LTD. (CH) | 1992-05-12 | — | — | US | disclosed |
| US-4939148-A | Amine derivatives, processes for their production and their use | SANDOZ, LTD. (CH) | 1990-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053468-B2 | Heterocyclic compound | RORC, RORB, RORA | TAAR1 941/4885EED 249/4885ABCG2 2345/4885 |
| US-20170050974-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | TAAR1 941/4885EED 249/4885ABCG2 2345/4885 |
| US-20180319812-A1 | HETEROCYCLIC COMPOUND | RORC, RORB, RORA | TAAR1 941/4885EED 249/4885ABCG2 2345/4885 |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | GRM5, GRM3, GRM1 | TAAR1 259/4885EED 1386/4885ABCG2 2197/4885 |
| US-20070299130-A1 | Benzopyran Compound | NR0B1, CYP2B6, RYR2 | TAAR1 1895/4885EED 1892/4885ABCG2 864/4885 |
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | TAAR1 1212/4885EED 3360/4885ABCG2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.